FDA: BPC-157 and other peptides flagged for significant safety risks
In September 2023 the FDA placed BPC-157 on its list of bulk drug substances that may present significant safety risks for compounding.
In September 2023 the FDA placed BPC-157 on its list of bulk drug substances that may present significant safety risks for compounding.

On September 29, 2023, the U.S. Food and Drug Administration placed BPC-157 in category 2 under section 503A — its list of bulk drug substances for use in compounding that may present significant safety risks. The agency's stated reasons matter for anyone working with peptides.
The FDA cited the possibility of immunogenicity for certain routes of administration. It pointed to the complexities that come with peptide-related impurities and with characterizing the active pharmaceutical ingredient itself. And it noted that there is little or no human safety information for the proposed routes of use.
The same list includes other peptides: AOD-9604, cathelicidin LL-37, epitalon, GHRP-2, and GHRP-6. For GHRP-2, the FDA noted reports of serious adverse events, while stating that causality had not been established.
The reasoning is the part to keep. The FDA is not saying these peptides simply "don't work." It is saying that with peptides, the hard problems are impurity profiling and identity characterization — exactly the things that make a batch reproducible and safe to characterize. Aggregates, truncated sequences, and residual impurities are not edge cases with peptides; they are routine manufacturing realities, and they are the reason a regulator flags immunogenicity risk.
That is the connection to a certificate of analysis. An impurity profile and an identity determination are not paperwork — they are the characterization work regulators say is difficult. A COA that reports identity (by mass), purity (by chromatography), and an impurity profile is answering the questions the FDA raises here.
FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
Regulator2026The FDA has warned about fraudulent and unapproved compounded GLP-1 products, including false labels and dosing-error adverse events.
Explainer2024What 'research use only' actually means, and how the FDA's position on peptides and unapproved GLP-1s frames it.